Saronyx

Saronyx is a biotechnology company dedicated to discovering and developing next-generation small molecule immunotherapies for the treatment of cancer. The company's primary focus is on the development of potent and selective inhibitors of CBL-B, an E3 ubiquitin ligase that acts as a negative regulator of T cell and NK cell activation. By inhibiting CBL-B, Saronyx aims to enhance the immune system's ability to recognize and eliminate tumor cells, potentially offering a new approach for patients with various solid tumors. The leadership team includes experienced drug hunters from companies like Exelixis, bringing significant expertise in small molecule drug discovery. Saronyx operates with a focus on high-value targets within the immuno-oncology space to address unmet medical needs in oncology.